News from the debiopharm group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 07, 2009, 02:30 ET

Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent

Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global...

Sep 03, 2009, 11:00 ET

The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection

Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Aug 04, 2009, 04:30 ET

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Jul 30, 2009, 04:58 ET

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Jul 21, 2009, 05:18 ET

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

Jun 23, 2009, 05:48 ET

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

May 11, 2009, 06:51 ET

Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA

- 1- 3- and 6-Month Formulations - A new Treatment for Prostate Cancer Patients in Switzerland Debiopharm Group (Debiopharm), a global...

Apr 30, 2009, 05:05 ET

Clinical Update - Debio 025 in Hepatitis C

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the...

Apr 28, 2009, 04:47 ET

Clinical Update - Debio 025 in Hepatitis C

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the...

Nov 20, 2008, 04:00 ET

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and...

Nov 17, 2008, 04:00 ET

Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly...

Nov 13, 2008, 16:00 ET

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and...

Nov 04, 2008, 11:19 ET

Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly...

Sep 02, 2008, 01:00 ET

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment

LAUSANNE, Switzerland, September 2 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist...

May 15, 2008, 01:00 ET

Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist...

Apr 14, 2008, 01:00 ET

Debiopharm and Airmid Sign Option and License Agreement for the Development of Debio 0824, an ShK Peptide for Autoimmune Disorders

LAUSANNE, Switzerland, April 14 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in...

Mar 04, 2008, 00:00 ET

Clinical Update - Debio 9902 SR in Alzheimer's Disease

LAUSANNE, Switzerland, March 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist...

Feb 27, 2008, 00:00 ET

Debiopharm and EPFL Establish an Oncology Chair

LAUSANNE, Switzerland, February 27 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist...

Oct 31, 2007, 01:00 ET

Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories

PARIS and LAUSANNE, Switzerland, Oct. 31 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN) and Debiopharm Group (Debiopharm), a global...

Oct 31, 2007, 01:00 ET

Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology

LAUSANNNE, Switzerland and CHIBA, Japan, October 31 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical...